Evidence map›Paper›PMID 30290312›Full record

ArticleVirology2018

Versatile targeting system for lentiviral vectors involving biotinylated targeting molecules.

Kathy Situ, Bernadette Anne Chua, Song Yi Bae, Aaron Samuel Meyer, Kouki Morizono

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Envelope protein-specific B cell receptors direct lentiviral vector tropism in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  5. Article
  6. Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kathy SituDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Bernadette Anne ChuaDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.
Song Yi BaeDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Aaron Samuel MeyerDepartment of Bioengineering, University of California, Los Angeles, Los Angeles, CA 90095, USA; Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA 90095, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Kouki MorizonoDivision of Hematology and Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA; UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA. Electronic address: koukimo@ucla.edu.

Funding

Adapter-Layer RTK Signaling: Basic Understanding & Targeted DrugResistanceDP5OD019815 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MEYER, AARON SAMUEL · 2014 to 2018
$2.0M
The roles of phosphatidylserine and its receptors in HIV replicationR01AI108400 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2013 to 2016
$1.4M
The role of envelope phosphatidylserine in the binding of HIV to target cellsR21AI095004 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORIZONO, KOKI · 2011 to 2012
$424k
NIAID NIH HHS R01 AI108400NIAID NIH HHS R21 AI095004NIH HHS DP5 OD019815
6 · The paper itself

Abstract

Conjugating certain types of lentiviral vectors with targeting ligands can redirect the vectors to specifically transduce desired cell types. However, extensive genetic and/or biochemical manipulations are required for conjugation, which hinders applications for targeting lentiviral vectors for broader research fields. We developed envelope proteins fused with biotin-binding molecules to conjugate the pseudotyped vectors with biotinylated targeting molecules by simply mixing them. The envelope proteins fused with the monomeric, but not tetrameric, biotin-binding molecules can pseudotype lentiviral vectors and be conjugated with biotinylated targeting ligands. The conjugation is stable enough to redirect lentiviral transduction in the presence of serum, indicating their potential in in vivo . When a signaling molecule is conjugated with the vector, the conjugation facilitates transduction and signaling in a receptor-specific manner. This simple method of ligand conjugation and ease of obtaining various types of biotinylated ligands will make targeted lentiviral transduction easily applicable to broad fields of research.

Indexed as

BiotinBiotinylationGene Expression Regulation, ViralGenetic VectorsGene Transfer TechniquesLentivirusTransduction, GeneticViral Envelope ProteinsBiotinViral Envelope ProteinsBiotinLentiviral vectorsRhizavidinSignalingStreptavidinTargeting

Identifiers

PMID30290312
PMCPMC6269213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.